Reactivity | MuSpecies Glossary |
Applications | Flow |
Clone | 2096C |
Clonality | Monoclonal |
Host | Rabbit |
Conjugate | Alexa Fluor 647 |
Additional Information | Recombinant Monoclonal Antibody. |
Immunogen | Mouse myeloma cell line NS0-derived recombinant mouse B7-H1 Met1-His239 Accession # Q9EP73 |
Specificity | Detects mouse B7-H1 in direct ELISAs and Western blots. |
Isotype | IgG |
Clonality | Monoclonal |
Host | Rabbit |
Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
Storage | Store the unopened product at 2 - 8 °C. Do not use past expiration date. |
Buffer | Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. |
Mouse B7 homolog 1(B7-H1), also called programmed death ligand 1 (PD-L1) and programmed cell death 1 ligand 1 (PDCD1L1), is a member of the B7 family of proteins that provide signals for regulating T-cell activation and tolerance (1-4). Other family members include B7-1, B7-2, B7-H2, B7-H3 and PD-L2. B7 proteins are immunoglobulin (Ig) superfamily members with extracellular Ig-V-like and Ig-C-like domains and a short cytoplasmic region. Among the family members, they share from 20-40% amino acid (aa) sequence identity. The cloned mouse B7-H1/PD-L1 cDNA encodes a 290 aa type I membrane precursor protein with a putative 18 aa signal peptide, a 220 aa extracellular region containing one V-like and one C-like Ig domain, a 22 aa transmembrane region, and a 30 aa cytoplasmic domain. Mouse and human B7-H1/PD-L1 share approximately 70% aa sequence identity. B7-H1/PD-L1 is one of two ligands for programmed death-1 (PD-1), a member of the CD28 family of immunoreceptors. The other identified ligand is PD-L2. Mouse B7-H1/PD-L1 and PD-L2 share approximately 34% aa sequence identity and have similar functions. B7-H1/PD-L1 is constitutively expressed in various lymphoid and non-lymphoid organs including placenta, heart, pancreas, lung, liver, and endothelium
(1‑4). The expression of B7-H1/PD-L1 is detected on B cells, T cells, monocytes, dendritic cells and thymic epithelial cells. IFN-gamma treatment induces B7-H1/PD-L1 expression in monocytes, dendritic cells, and endothelial cells. B7-H1/PD-L1 expression is also upregulated in a variety of tumor cell lines. On previously activated T cells, B7-H1/PD-L1 interaction with PD-1 inhibits TCR-mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. In contrast, a costimulatory function for the PD-1 ligands on resting T cells has also beenreported (1-4).
Secondary Antibodies |
Isotype Controls |
Unlocking the Potential of Biosimilars in Immuno-Oncology By Jennifer Jones, M.S.Biosimilar Antibodies: Imitation Meets InnovationIn the ever-evolving medical landscape, a new class of pharmaceuticals is emerging as a game-changer, poised to transform the way we approach... Read full blog post. |
Synthetic Biotic Medicine as Immunotherapy Against Cancer: Evidence From Arginine-Producing Engineered Bacteria By Jamshed Arslan, Pharm D, PhDWhat do nuts, dairy and red meat have in common? In addition to the fact that they are all edible, one of the answers is L-arginine. This amino acid improves T cell’s respons... Read full blog post. |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Uniprot |
|